Loading...
•
Mar 31, 2023
Ultragenyx Q1 2023 Earnings Report
Ultragenyx reported strong revenue growth driven by Crysvita and Dojolvi, and advanced clinical programs.
Key Takeaways
Ultragenyx reported a 26% increase in total revenue for Q1 2023, driven by Crysvita and Dojolvi. The company is progressing with clinical programs, including UX143 and GTX-102, and reaffirms its 2023 revenue guidance.
Total revenue for Q1 2023 was $100.5 million, a 26% increase compared to Q1 2022.
Crysvita revenue reached $76.0 million, demonstrating 28% growth year-over-year.
Dojolvi revenue was $14.3 million for Q1 2023.
The company reaffirmed its 2023 total revenue guidance of $425 million to $450 million.
Revenue by Segment
Forward Guidance
Ultragenyx reaffirms its financial guidance for 2023.
Positive Outlook
- Total revenue is expected to be in the range of $425 million to $450 million.
- Crysvita revenue is projected to be between $325 million and $340 million.
- Dojolvi revenue is anticipated to be in the range of $65 million to $75 million.
- Net cash used in operations is expected to be less than $400 million.
- Phase 2 data and Phase 3 initiation of UX143 expected in mid-2023
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...